News articles about RadNet (NASDAQ:RDNT) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. RadNet earned a news impact score of 0.10 on Accern’s scale. Accern also gave media coverage about the medical research company an impact score of 47.4350505612742 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Here are some of the media stories that may have impacted Accern’s analysis:

Several research analysts recently issued reports on the company. BidaskClub lowered RadNet from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 11th. ValuEngine raised RadNet from a “hold” rating to a “buy” rating in a research report on Wednesday, May 2nd. Finally, Zacks Investment Research raised RadNet from a “sell” rating to a “hold” rating in a research report on Wednesday, May 16th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, two have issued a buy rating and two have assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $14.75.

NASDAQ:RDNT traded up $0.20 during trading hours on Friday, hitting $14.10. 128,336 shares of the company were exchanged, compared to its average volume of 171,176. The firm has a market cap of $678.40 million, a P/E ratio of 48.62, a P/E/G ratio of 5.02 and a beta of 0.32. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 4.49. RadNet has a one year low of $9.50 and a one year high of $15.50.

RadNet (NASDAQ:RDNT) last announced its earnings results on Thursday, August 9th. The medical research company reported $0.11 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.13 by ($0.02). The company had revenue of $244.40 million for the quarter, compared to the consensus estimate of $239.34 million. RadNet had a positive return on equity of 17.00% and a negative net margin of 0.64%. The firm’s revenue for the quarter was up 6.3% on a year-over-year basis. During the same period in the prior year, the business earned $0.11 earnings per share. equities research analysts expect that RadNet will post 0.35 EPS for the current year.

In other news, insider Norman R. Hames sold 10,000 shares of RadNet stock in a transaction dated Friday, June 8th. The stock was sold at an average price of $12.81, for a total value of $128,100.00. Following the completion of the transaction, the insider now directly owns 312,450 shares of the company’s stock, valued at approximately $4,002,484.50. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders have sold 50,000 shares of company stock valued at $676,200. 7.56% of the stock is owned by corporate insiders.

About RadNet

RadNet, Inc, together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services.

Featured Story: Outstanding Shares

Insider Buying and Selling by Quarter for RadNet (NASDAQ:RDNT)

Receive News & Ratings for RadNet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet and related companies with MarketBeat.com's FREE daily email newsletter.